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Background: Preclinical and clinical studies suggest that supplementation with omega-3 fatty acids after trauma
might reduce subsequent posttraumatic stress disorder (PTSD). To date, we have shown in an open trial that PTSD
symptoms in critically injured patients can be reduced by taking omega-3 fatty acids, hypothesized to stimulate
hippocampal neurogenesis. The primary aim of the present randomized controlled trial is to examine the efficacy of
omega-3 fatty acid supplementation in the secondary prevention of PTSD following accidental injury, as compared
with placebo. This paper describes the rationale and protocol of this trial.
Methods/design: The Tachikawa Project for Prevention of Posttraumatic Stress Disorder with Polyunsaturated Fatty
Acid (TPOP) is a double-blinded, parallel group, randomized controlled trial to assess whether omega-3 fatty acid
supplementation can prevent PTSD symptoms among accident-injured patients consecutively admitted to an
intensive care unit. We plan to recruit accident-injured patients and follow them prospectively for 12 weeks.
Enrolled patients will be randomized to either the omega-3 fatty acid supplement group (1,470 mg
docosahexaenoic acid and 147 mg eicosapentaenoic acid daily) or placebo group. Primary outcome is score on the
Clinician-Administered PTSD Scale (CAPS). We will need to randomize 140 injured patients to have 90% power to
detect a 10-point difference in mean CAPS scores with omega-3 fatty acid supplementation compared with
placebo. Secondary measures are diagnosis of PTSD and major depressive disorder, depressive symptoms,
physiologic response in the experiment using script-driven imagery and acoustic stimulation, serum brain-derived
neurotrophic factor, health-related quality of life, resilience, and aggression. Analyses will be by intent to treat. The
trial was initiated on December 13 2008, with 104 subjects randomized by November 30 2012.
Discussion: This study promises to be the first trial to provide a novel prevention strategy for PTSD among
traumatized people.
Trial registration: ClinicalTrials.gov Identifier NCT00671099
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Accidental injury occurs worldwide and accounted for
approximately 16% of the world’s burden of disease in
1998 [1]. Advances in injury care systems have since
increased the number of seriously injured people who
can survive their injuries [2] and severely injured
patients might be at higher risk for developing posttrau-
matic stress disorder (PTSD) [3]. The prevalence of
PTSD determined by structured clinical interviews with
injured patients consecutively admitted to intensive care
units (ICUs) or emergency departments is in the range
of 5–30% at 0–3 months after accidental injury [4-10] to
2–23% at 4–12 months after [4-8,10-12]. Comorbidity
between PTSD and depressive disorder is also highly
prevalent in these injured patients [4,9,13]. Among Japa-
nese patients admitted to the ICU at our hospital after
motor vehicle accident (MVA), 8% developed full PTSD,
16% developed partial PTSD, and 23% developed depres-
sive disorder (16% major depressive disorder, 7% minor
depressive disorder) at 1 month after accidental injury
[9]. This amounts to roughly one in every four patients
developing some form of PTSD after MVA. The need
for a selective, preventive intervention strategy is there-
fore clear.
A few studies have reported some positive outcomes
in regard to preventing PTSD. These include a rando-
mized controlled trial of cognitive therapy given in the
initial months after MVA [14], an open trial of propran-
olol after accidental injury in a small study population
[15], and a randomized controlled trial of propranolol
after accidental injury in a small study population [16].
In Japan, however, psychiatric services provided in emer-
gency hospitals are limited [17] and currently fall short
of providing adequate and effective psychiatric care.
A growing number of epidemiological studies suggest
an association between depression and low dietary in-
take of omega-3 fatty acids [18-21]. Although several
studies have pointed out discrepancies relating to the
differential effects of eicosapentaenoic acid (EPA, 20:5n-
3) versus docosahexaenoic acid (DHA, 22:6n-3), previ-
ous meta-analyses are supportive of omega-3 fatty acid
supplementation in reducing depressive symptoms
[22-27]. However, there have been no trials on PTSD
conducted thus far. Several biological mechanisms po-
tentially explain the effects of omega-3 fatty acids on
psychiatric illness, especially mood and anxiety disorder
[22]. Animal studies have revealed that short-term aug-
mentation of dietary omega-3 fatty acids relative to
omega-6 fatty acids up-regulated adult neurogenesis
[28], and that dietary omega-3 fatty acids elevated levels
of brain-derived neurotrophic factor (BDNF), which pro-
motes neuronal survival and growth [29]. In addition,
DHA was shown to increase neurite extension and
branching of hippocampal neurons in vitro [30] as wellas the maturation of neurons and hippocampal neuro-
genesis in adult rats [31]. Venna at al. showed that the
increase in newborn hippocampal cells by polyunsatur-
ated fatty acids occurred in parallel with an increase in
hippocampal volume and over-expression of BDNF
mRNA and protein in the hippocampus [32].
The hippocampus is crucial for converting short-term
memory into long-term memory [33] and can process
and temporarily store new memory during the transition
period before transferring labile memory to the cortex
for permanent storage [34]. In the pathogenesis of
PTSD, fear memory becomes excessively consolidated
and extinction learning does not progress [35]. Kitamura
et al. recently found that the period of hippocampus-
dependent fear memory is longer in mice with decreased
hippocampal neurogenesis and shorter in mice with ac-
tive hippocampal neurogenesis [36], indicating that the
level of hippocampal neurogenesis is a crucial factor in
determining the duration of hippocampal-dependent
fear memory. The possibility arises then that the fear
memory characteristic to PTSD might be controllable by
aptly regulating hippocampal neurogenesis [37].
We hypothesized that promoting adult neurogenesis
early in the transition period might facilitate clearance of
fear memory in humans [37]. Our preliminary open trial
found that post-trial PTSD symptoms were significantly
alleviated in injured patients who all took the omega-3
fatty acids compared with historical controls [38,39].
The present study aims to examine the effectiveness of
omega-3 fatty acids for preventing PTSD in physically
injured patients admitted to the ICU at National Disas-
ter Medical Center, Japan immediately following acci-
dental injury (mostly MVA). This study is called the
Tachikawa Project for Prevention of PTSD with Polyun-
saturated Fatty Acid (TPOP).
Methods
Study design
TPOP is a double-blinded, parallel group, randomized
controlled trial that compares an intervention group that
receives omega-3 fatty acid supplementation with a par-
allel control group that receives placebo supplementa-
tion. This study was registered at http://clinicaltrials.
gov/ct2/show/NCT00671099.
Participants/eligibility criteria
Participants are solely recruited from the ICU of the Na-
tional Disaster Medical Center. The following inclusion
criteria apply to patients with accidental injury: (1) aged
18 years or older; (2) a native Japanese speaker or non-
native speaker with Japanese conversational ability; (3)
contact with us within 240 h after injury; and (4) phys-
ical and psychological ability to understand the scope of
the present trial and to provide written consent for study
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lowing: (1) acute brain parenchymal damage that is obvi-
ously irretrievable or subdural or subarachnoidal
bleeding detected by computed tomography and/or
magnetic resonance imaging; (2) cognitive impairment,
defined as a score of <24 on the Mini-Mental State
Examination [40]; (3) a serious drinking problem or high
γ-GTP blood level of ≥100 IU/L on admission; (4) a
smoking habit of ≥40 cigarettes per day; (5) history and
current suspicion of psychosis or bipolar I disorder; (6)
suspicion of alcohol- or capsule-related disorder or eat-
ing disorder; (7) serious psychiatric symptoms such as
suicidal ideation, self-harm behavior or severe dissoci-
ation, or in need of rapid psychiatric treatment; (8) regu-
lar treatment with anti-epilepsy medication, lithium,
ethyl icosapentate, aspirin, or warfarin within the last 3
months; (9) regular consumption of polyunsaturated
fatty acid supplements within the last 3 months; and
(10) a habit of eating fish ≥4 times per week, to ensure
comparability to patients studied in Western countries.
All participants receive a gift voucher for their partici-
pation after each assessment (1,000 JPY [11 USD] during
hospitalization, 2,000 JPY [22 USD] after discharge).
Enrollment procedure
Patients receive a comprehensive physical examination
including computed tomography or magnetic resonance
imaging before the study commences. Eligible patients
are screened through the daily conference records for
patients newly admitted to the ICU in cooperation with
physicians in the Department of Critical Care and Trau-
matology. From the viewpoint of ethical concerns, all
patients are given a self-help leaflet entitled Understand-
ing Your Reactions to Accidental Injury before checking
the criteria. After receiving a psychological education
session for 15–20 min, patients are invited to participate
in the study by clinical research coordinators who are
well-trained nurses with a Master’s degree in Clinical
Psychology. The overall procedure of the trial is shown
in Figure 1.
Informed consent
The following information is used in obtaining consent
from eligible participants.
1. Participation in the study is voluntary, and non-
participants will not be penalized in any way.
Participants can withdraw from the study at any
time even after starting participation in the study.
2. The purpose of the study is to examine whether
omega-3 capsules are effective in alleviating mental
stress after physical trauma compared with placebo
capsules in patients with physical trauma
transferred to an emergency room.3. Participants will be randomly assigned to either of
the two intervention groups. Participants in both
groups will be interviewed at 1 month and 3
months after providing consent.
4. Effectiveness of the intervention will be assessed
through interviews as well as testing capsules
related to the autonomic nervous systems and
biological defense mechanism and neurotrophic
factors.
5. Participants surveyed during their hospital stay will
receive an incentive item for each interview.
Because those who are surveyed after discharge will
need to visit the hospital more frequently than usual
resulting in increased transportation costs, they will
receive incentive items to cover additional
transportation costs.
6. Participants will be contacted via telephone, email,
or confidential letters. To avoid inconveniencing the
participants, their families may be contacted within
the agreed conditions.
7. Collected information will be securely stored to
protect personal information. Before analysis,
identifying information such as name, address,
telephone number, date of birth, and patient record
number will be removed and new numbers will be
assigned (making the data anonymous).
8. All biological samples will be locked in a
refrigerator or freezer in the laboratory. They will
be stored over the long term because analyses will
be conducted after all clinical trials are completed
and the materials are needed later for confirmatory
experiments.
9. In cases where a new health problem develops
during the study, no special compensation will be
provided to such participants, but a physician will
examine and treat them under universal health
insurance.
10. Participants will be immediately provided with
information related to the study, including that which
may affect their decision to participate in the study.
11. At the request of participants, they can examine any
materials such as the research plan, except for other
patients’ information.
12. Results from this study may be utilized to improve
intervention for mental health treatment for large-
scale natural and/or human-made disasters in
the future.
13. The study results will be reported by our research
team and presented in medical journals and at
conferences. However, participants’ personal
information will not be revealed.
14. If a patent is granted based on the findings of the
study, it will be owned by the principal investigator
and the research institute.





Allocated to omega 3 fatty
acid supplementation (n=)
Psychological first aidprovided by clinical psychologist
Completion of 4 week
Follow up assessment (n=)
Completion of 12 week
Follow up assessment (n=)
Assessment of eligibility
Completion of 12 week
Follow up assessment (n=)
Completion of 4 week
Follow up assessment (n=)
Figure 1 Flow diagram of the study.
Matsuoka et al. BMC Psychiatry 2013, 13:8 Page 5 of 14
http://www.biomedcentral.com/1471-244X/13/815. This study will be conducted with public funding.
16. Participants can contact the investigators if they
have any questions.
Informed consent is obtained from eligible patients as
follows. Clinical research coordinators first explain the
potential public health benefits of the study results as
well as the study procedures. Coordinators then explain
the study plan, intervention methods, evaluation meth-
ods, and means used to obtain information. Eligible
patients may take as much time as necessary to assess
the information and to decide whether to participate or
not. After the study is explained, written documented
consent is obtained, and their participation starts (inves-
tigators make sure the consent has been filed in the
medical record).
During a hospital stay, meetings are regularly held
with the participants to ensure they clearly understand
some study aspects that lay people may not easily under-
stand, such as the study purpose and treatment assign-
ment. They are asked to strictly adhere to taking the test
capsules.
Intervention
Participants are asked to take 7 capsules per day after
eating for 12 weeks and additionally told that they might
take a full day’s dosage at one time. Concomitant psychi-
atric medications are not allowed during the study
period except for minimal and intermittent use of hyp-
notics and antidepressants.Active omega-3 capsule
We prepared new capsules for this trial, containing a
higher concentration of DHA than used in our previous
trial [41]. Each capsule contains 300 mg of oil with 0.3%
alpha-tocopherol. A total of 7 capsules containing 1470
mg DHA and 147 mg EPA are administered daily.Placebo capsule
The content of the control oil was slightly modified from
our previous study [42]. The present control oil is a mix-
ture of rapeseed oil (47%), soybean oil (25%), olive oil
(25%), fish oil (3%), and 0.3% α-tocopherol. The fatty
acid composition of this mixture is similar to the average
composition of fatty acid intake in Japan. We added a
small amount of not fully deodorized fish oil to the base
of the control oil to make it fishy and undistinguishable
from the active oil.Management of intervention
During hospitalization, ward nurses administer all cap-
sules and confirm that participants take them. In the
case of discharge before completing the trial, partici-
pants take the capsules by themselves, and clinical re-
search coordinators telephone or email them to confirm
at least once a week. Our weekly e-newsletters are also
sent to the participants to maintain their interest in the
study and to provide general health care advice. If parti-
cipants forget to take capsules, they are asked to take a
double dose on the next day or later.
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An independent statistician (Dr. Akiko Kada) composed
tables of block randomization with three stratification
factors using a computer-generated random allocation
sequence. Stratification factors included sex, age (<40 or
≥40 years), and sense of life threat. This resulted in eight
(2×2×2) different stratified tables of supplement num-
bers. Those tables were sent to an independent pharma-
cist (Professor Satoru Kobayashi); he securely kept the
tables and prepared numbered supplements bottles
according to the tables. Both the research team and par-
ticipants will be blinded to randomization until the last
participant has completed the protocol and the spread-
sheets of all results are finalized. Stratification by sex,
age, and sense of life threat has been justified by previ-
ous studies; the prevalence of PTSD and major depres-
sive disorder were higher in women than in men [43,44];
and our previous cohort study of MVA survivors showed
that sense of life threat was a strong predictor of subse-
quent PTSD [9]. Moreover, according to the National
Health and Nutrition Survey on food group consump-
tion by age group, the amount of meat products con-
sumed such as pork and beef is higher for both sexes
before age 40, but after this age the amount of seafood
consumption increases. Also omega 3 fatty acid contents
in red blood cells increase with age in the Japan popula-
tion [45].
Baseline assessment
Baseline data are collected on enrollment on the follow-
ing items: general socio-demographics, smoking and al-
cohol consumption habits, detailed information about
the accident, Injury Severity Score [46], Glasgow Coma
Scale score [47], mild traumatic brain injury (i.e., con-
cussion) defined by Hoge’s criteria [any of the following
three conditions: losing consciousness (knocked out),
being dazed, confused or seeing stars, or not remember-
ing the injury] [48], type of accident, vital signs first
assessed at the accident site and in the emergency room,
regular medication, inhalation analgesic, past medical
history, family history of psychopathology as determined
in a structured interview, a sense of life threat during
the accident as determined in the structured interview,
the extent of memory regarding the accident as evalu-
ated by the Memory of Traumatic Event Questionnaire
[49], bodily pain at rest and on effort as measured sub-
jectively using a visual analogue scale [50], performance
status as defined by the Eastern Cooperative Oncology
Group [51], and past history of traumatic event using
the trauma checklist of the Clinician Administered
PTSD Scale (CAPS) [52,53]. Other employed instru-
ments include: the Peritraumatic Distress Inventory
(PDI) [54,55], Conner-Davidson Resilience Scale (CD-
RISC) [56], Buss-Perry Aggression Questionnaire (BAQ)[57], and the Food Frequency Questionnaire (FFQ)
[58,59]. In a validation study, relatively high correlations
between fatty acid intakes estimated from the FFQ and
the corresponding serum phospholipid levels were
observed as follows: EPA, r = 0.43 and r = 0.59 and
DHA, r = 0.35 and r = 0.49 for crude value (g/day) and
percentage of total fatty acid intake, respectively [60].
Biological samples
Routine laboratory examination
Hematological parameters: white blood cell, erythrocyte,
platelet, hemoglobin, and hematocrit.
Biochemistry: total protein, total albumin, total choles-
terol, creatinine, BUN, GOT, GPT, γGTP, C-reactive
protein.
Erythrocytes for fatty acid analysis
Seven milliliters of whole blood are obtained with ethylene-
diamine tetraacetic acid in the emergency room (before
ICU admission, baseline) and at the 3-month assessment
for determination of fatty acids. Erythrocytes are washed
twice with saline and frozen at −80°C until analysis. Total
lipids are extracted according to the method of Bligh and
Dyer [61]. Total phospholipid fractions are separated by
thin-layer chromatography. After transmethylation with
HCl–methanol, the fatty acid composition is analyzed by
gas chromatography (GC-2014 Shimadzu Corporation,
Kyoto, Japan) equipped with a DB-225 capillary column
(length, 30 m; internal diameter, 0.25 mm; film 0.25 μm;
J&M Scientific, Folsom, CA). The entire system is con-
trolled using the gas chromatography software GC-solution
version 2.3 (Shimadzu Corporation, Kyoto, Japan).
Serum for BDNF analysis
To assess the serum level of BDNF, 7–10 ml of blood
are drawn at baseline, 1 month, and 3 months, and
serum samples are stored in separate freezers at −80°C
until analysis. We analyze all samples on the same day
and under the same conditions. For the baseline blood
sample, it is difficult to control for diurnal variation be-
cause the accident and admission can occur at any time;
however, all blood samples at 1 month and 3 months are
drawn between 10:00 and 16:00. Serum BDNF levels are
measured using the BDNF Emax Immunoassay System
kit (Promega, Madison, WI) according to the manufac-
turer’s instructions. The biochemist is blind to the diag-
nostic status of the participants. Other biomarkers such
as neuropeptide-Y, dehydroepiandrosterone, activin A,
and amino acids are also measured for comparison.
Outcome measures
Psychiatric evaluations
The primary efficacy variable is the total score on the
CAPS-DX [52,53]. Because there is potential overlap
Matsuoka et al. BMC Psychiatry 2013, 13:8 Page 7 of 14
http://www.biomedcentral.com/1471-244X/13/8between organic and psychogenic symptoms with regard
to PTSD, we will take care to ensure the symptoms are
psychogenic in origin. Generally, if a symptom is better
accounted for by an alternative explanation, we will
categorize it as not being a psychological symptom [62].
Because injured patients involved in accidents often ex-
perience partial or full loss of traumatic memory, it can
sometimes be difficult to differentiate organic from psy-
chogenic amnesia on item 8 (psychogenic amnesia in
criterion C3) of the CAPS. In this study, we adopt the
standard manner of calculating all items for assessing
PTSD symptoms as the primary outcome.
The secondary efficacy variables consist of the follow-
ing: PTSD diagnosis as determined by CAPS-DX with
all items including item 8, CAPS-DX total scores with-
out item 8 when assessing PTSD symptoms [8], PTSD
diagnosis as determined by CAPS-DX scores without
item 8, total scores on the Montgomery-Asberg Depres-
sion Rating Scale (MADRS) [63,64], and major depres-
sive disorder (MDD) as determined by the Mini
International Neuropsychiatric Interview (MINI) [65,66].
Other secondary outcome measures are described else-
where. Trained psychiatrists (YM, DN) conduct all of
the face-to-face structured interviews for the evaluation
of PTSD and other psychiatric morbidity at 1 and 3
months.
In this trial, participants are deemed to have partial
PTSD if they fulfill two of three symptom criteria [B (re-
experiencing), C (avoidance), or D (hyper-arousal)], and
also the criteria A-1 (stressor), E (duration), or F (im-
pairment). The inter-rater reliability of the diagnosis of
PTSD and MDD was reported previously [67].
Psychological and psychophysiological evaluations
1. Impact of Event Scale-Revised [68]
The Impact of Event Scale-Revised (IES-R) is a self-
reporting questionnaire about PTSD symptoms that
was developed in the U.S. It is the most widely used
measure internationally in all forms of disaster-area
research. The IES-R is composed of 22 items on the
three largest symptoms in the diagnostic criteria of
PTSD, namely re-experiencing, avoidance, and
increased physiological arousal. Respondents rate
symptoms experienced in the previous week. The
validity and reliability of the Japanese version of the
IES-R has been confirmed [69].
2. Hospital Anxiety and Depression Scale [70]
The Hospital Anxiety and Depression Scale (HADS)
includes a 7-item anxiety subscale and a 7-item
depression subscale for assessing general
psychological distress for the preceding week. Each
item is rated on a scale of 0–3, with high scores
denoting greater psychological distress. The validityand reliability of the Japanese version of the HADS
has been confirmed [71].
3. The Medical Outcomes Study 36-Item Short Form
Health Survey [72]
The Medical Outcomes Study 36-Item Short Form
Health Survey (SF-36) is based on a conceptual
model consisting of physical and mental health
constructs, and is designed to measure perceived
health status and daily functioning. It consists of 36
items scored in the following 8 domains: physical
functioning, role-physical functioning, bodily pain,
general health perception, vitality, social functioning,
role-emotional functioning, and mental health [73].
The validity and reliability of the Japanese version of
the SF-36 has been confirmed [74].
4. Connor-Davidson Resilience Scale [56]
The self-rating Connor-Davidson Resilience Scale
(CD-RISC) comprises of 25 items, each rated on a 5-
point scale (0–4), with high scores reflecting greater
resilience. The Japanese version of the CD-RISC was
translated by Nakajima and Kim and they are
currently conducting a validation study.
5. Buss-Perry Aggression Questionnaire [57]
The Buss-Perry Aggression Questionnaire (BAQ) is a
29-item questionnaire where participants rank
certain statements along a 5-point continuum from
"extremely uncharacteristic of me" to "extremely
characteristic of me." The scores are normalized on a
scale of 0 to 1, with 1 being the highest level of
aggression. It has 4 dimensions of aggression:
physical aggression, verbal aggression, anger, and
hostility. The validity and reliability of the Japanese
version of the BAQ has been confirmed [75].
6. Physiological assessment
To avoid any confounding effect that the
psychological and psychiatric assessment might have
on autonomic response, we perform the physiologic
assessment first [76]. The physiological data to be
collected include heart rate, skin conductance, and
continuous blood pressure while the patient is
subjected to startling tones and idiographic trauma-
related cues. The startling tones to be used in this
study are essentially the same as those described in a
previous study [77]. The idiographic script-driven
imagery to be used is essentially the same as that
described in a previous study [78]. The detailed
experimental procedures were reported elsewhere [79].Data collection schedule
Data collection listed is conducted according to the ap-
propriate timing and each aspect of the relevant infor-
mation. The follow-up assessment schedule from
baseline to 3 months is shown in Table 1.

















Alcohol, smoking, FFQ +
PDI +
Life event after the
accident
+ +
Serum + + +
Erythrocyte + +
Table legend text: CAPS, Clinician-Administered PTSD Scale; MINI, Mini
International Neuropsychiatric Interview; MADRS, Montgomery-Asberg
Depression Rating Scale; IES-R, Impact of Event Scale revised; HADS, Hospital
Anxiety and Depression Scale; SF-36, The 36-item short form of the MOS
Questionnaire; CD-RISC, Conner-Davidson Resilience Scale; BAQ, Buss-Perry
Aggression Questionnaire; FFQ, Food Frequency Questionnaire; PDI,
Peritraumatic Distress Inventory.
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1. Whole blood and serum: A blood sample is taken
from patients when transferred to our emergency
room and treated for the first time. If consent to
participate in the study is provided, test samples are
obtained by the Clinical Laboratory Department.
2. Demographic characteristics
3. Alcohol, smoking, food frequency questionnaire
(FFQ)
4. Detailed information about accidental injury
5. Psychological response to accidental injury: sense of
life threat, subjective severity of injury, MTEQ, PDI
6. Psychological assessment: CD-RISC, BAQ
7. Physical examination: Performance status, blood
pressure at rest (right hand), heart rate, laboratory data
Data collected at 1 month after informed consent provided
1. Life events after accidental injury
2. Outpatient or inpatient treatment
3. Physical examination: Performance status, blood
pressure at rest (right hand), heart rate, laboratory
data4. Psychiatric evaluation: MINI, CAPS, MADRS
5. Psychological response: IES-R, HADS
6. Serum
7. Adverse events
Data collected at 3 months after informed consent provided
1. Life events after accidental injury
2. Outpatient or inpatient treatment
3. Physical examination: Performance status, blood
pressure at rest (right hand), heart rate, laboratory
data
4. Psychiatric evaluation: MINI [65,66], CAPS [52,53],
MADRS [63,64]
5. Psychological responses: IES-R, HADS, SF-36, CD-
RISC [56], BAQ [57]
6. Physiological assessment
7. Whole blood and serum
8. Adverse events
9. Number of days of leave from work taken from the
time of injury
Procedure of psychiatric evaluation
Trained psychiatrists (YM, DN) conduct all of the face-to-
face structured interviews for the evaluation of PTSD and
other psychiatric morbidity at months 1 and 3. The pri-
mary method of evaluation is set as the face-to-face inter-
view. However, conducting an interview via phone is also
acceptable when an interview proves difficult to arrange.
Clinical research coordinators notify participants of the
upcoming follow-up survey no later than 5 days before a
psychiatric evaluation. An outcome evaluator reserves a
date for the next evaluation after the survey. When notify-
ing participants via e-mail, an email template created spe-
cifically for this study is used and sent from an email
account address designated for this study.
Reporting of adverse events and protection of
participants
An adverse event is defined as any unwanted or unin-
tended sign, symptom, or disease seen in trial partici-
pants, regardless of the causal relationship with the
study interventions. After enrollment, patients undergo
a short physical examination and then complete the
questionnaires and interviews. Safety issues concerning
omega-3 fatty acid supplementation, including monitor-
ing of vital signs and records of adverse events, are
investigated at least twice a week during hospitalization.
After discharge, safety issues are checked by telephone
or email contact. When an adverse event is suspected,
researchers and clinical research coordinators evaluate
and record the event. Based on the following criteria,
adverse events are evaluated for severity according to
the following three levels.
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participant can continue the trial without treatment.
2. Moderate: Some symptoms or signs observed, but
the participant can continue the trial with treatment,
such as reducing the dose of the test capsules or
administering drugs.
3. Severe: Clinical status and daily activities are
significantly affected, and discontinuation of the test
capsules may be needed. Examples include headache,
diarrhea, soft stool, and belching that are severe
enough to reduce daily activities.
An association between the adverse event and test cap-
sules is evaluated on four levels based on the following
criteria. If it is judged there is “No association,” the reason
for the judgment is also explained in the report.
1. Not related: Symptoms can be clearly explained by
factors other than the test capsules.
2. Possibly related: Although the symptoms can be
considered to be caused by factors other than the
test capsules, a possible relationship between them
cannot completely be ruled out.
3. Probably related: The symptoms are unlikely to be
caused by factors other than the test capsules.
4. Related: Causal relationship with the test capsules is
strongly suspected, due to a temporal relationship
between test capsule administration and occurrence
of the adverse event, a correlation between the dose
of the test capsules and symptom severity, or when
occurrence of the adverse event cannot be explained
by factors other than the test capsules.
Serious adverse events include the following, regard-
less of the dose of the test capsules. Administration of
the test capsules is discontinued upon the occurrence of
any such event.
1. An event resulting in death
2. A life-threatening event (the participant is facing the
possibility of death at the occurrence of the event)
3. An event requiring hospitalization or an extension of
hospitalization to provide treatment
4. An event resulting in permanent or prominent
disorder or functional failure
5. An event causing a subsequent congenital anomaly
or congenital deficiency
6. Other events or reactions considered medically
significant
Clinical research coordinators immediately contact the
principal investigator (YM) and research committee
when an adverse event or serious adverse event occurs.
Any adverse event or serious adverse event is reportedon a monitoring report and evaluated by the Data and
Safety Monitoring Board regularly. A reported event
gives the date of occurrence and description of the
event. In addition, information is reported on the dose
of the capsule, concomitant drug(s) and dosage, con-
sumed supplements, types of food, and dates of start or
discontinuation of the test capsules. The principal inves-
tigator gathers information about the occurrence of a
serious event or event that may affect study continu-
ation. The principal investigator also communicates and
shares the information with the Data and Safety Moni-
toring Board independently from the other researchers
and the provider of the test capsules. The ethics com-
mittee receives reports as needed.
Failure to attend a hospital visit or failure to reach the
participant or family
If a participant does not visit the hospital for a follow-up
appointment, the clinical research coordinator calls the
participant or their family and encourages a visit soon
after confirming the reason for not visiting. If visiting is
judged to be difficult, a phone interview is conducted
instead. When contacting the participant, the coordinator
confirms that the person talking over the phone is the
participant himself or herself. When mailing materials, a
confidential form is used to protect personal information.Outcomes
Primary outcome
Total score of the CAPS-DX at 3 months follow-up.
Secondary outcomes
1. Incidence of diagnosis of PTSD (full PTSD and
partial PTSD) at 1 and 3 months follow-up
2. Total score of the CAPS-DX at 1 month follow-up
3. MADRS score at 1 and 3 months follow-up
4. Incidence of diagnosis of major depressive disorder
evaluated by MINI at 1 and 3 months follow-up
5. Physiological response to script-driven imagery and
audiovisual stimuli at 3 months follow-up
6. IES-R score at 1 and 3 months follow-up
7. HADS score at 1 and 3 months follow-up
8. SF-36 score at 1 and 3 months follow-up
9. CD-RISC score at baseline and 3 months follow-up
10. BAQ score at baseline and 3 months follow-up
11. Serum BDNF at baseline and 1 and 3 months follow-up
12. Number of days of leave from work taken from the
time of injury
13. Dehydroepiandrosterone at 1 and 3 months follow-up
14. Neuropeptide Y at 1 and 3 months follow-up
15. Interleukin 1 beta at 1 and 3 months follow-up
16. Interleukin 6 at 1 and 3 months follow-up
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follow-up
18. D-serine at 1 and 3 months follow-up
19. L-serine at 1 and 3 months follow-up
20. DL-serine at 1 and 3 months follow-up
21. Activin at 1 and 3 months follow-up
Statistical analyses
All analyses are conducted according to the intention-
to-treat principle.
Primary analysis
The primary purpose of this trial is to examine whether
patients receiving omega-3 fatty acid supplementation
after physical trauma score on average 10 points lower
on the CAP scale at 3 months follow-up than those re-
ceiving placebo. Using analysis of covariance, mean score
differences, 95% confidence intervals, and P values are
calculated. Two-tailed tests will be used, and the α level
will be set at 5%. If background factors are found that
may influence prognosis even if the assignment code is
blinded, those factors will be entered as covariates in the
analysis.
Exploratory analysis
To complement the primary analyses, additional evalu-
ation of secondary outcomes and sub-groups will be
analyzed. The analysis will be exploratory, thus multipli-
city will not be controlled. Evaluation with regression
models in repeated measures as a mixed effect model
will be conducted. Sensitivity analysis and imputed
methods to missing variables will be used to examine
the validity of the findings.
Estimation of sample size
Forty-nine cases are required, given that the expected
CAP score difference between the groups at 3 months is
set as 10, with an α level of 0.05 (two-tailed), a β level of
.10, and standard deviation of 15. Discontinuation and
dropout are estimated to be around 30% of the partici-
pants, indicating that 70 cases are needed. Thus, the
desired number of participants in each group is 70, with
a total of 140 cases. However, if this trial becomes diffi-
cult to continue due to finances, man-power, or physical
factors, there is a possibility that the accumulation of
cases will be stopped before the desired number is
achieved.
Time periods of the study
Study period: December 2008 through December 2013
Enrollment period: December 2008 through June 2013
Follow-up period: December 2008 through December
2013Ethical considerations
The present study protects the rights and welfare of par-
ticipants in the spirit of ethical guidelines outlined under
the Declaration of Helsinki. The study further respects
the ethical principles of the Ministry of Health, Labour,
and Welfare of Japan. Confidence is assured in the eth-
ics, safety, scientific rigor, and reliability of the research.
Personal information obtained in the course of the
research is strictly secured to avoid external leaks. No
special compensation is paid in the event of health dam-
age directly related to the research. The research plan
(2007–12) was deliberated upon and approved by the
Ethics Committee of the National Disaster Medical Cen-
ter on February 8, 2008.Criteria for discontinuing intervention, evaluation, and
follow-up
The criteria for discontinuing intervention, evaluation,
and follow-up with participants are set as follows.Discontinuing intervention
Investigators discontinue the intervention if the par-
ticipant refuses to continue the treatment with the
test capsules or placebo, or if further intervention is
difficult because concomitant drug administration is
required medically. Investigators ask the participant
whether he or she can participate in later evaluations
and follow-up. The process for discontinuing registration
is initiated and reasons for the discontinuation are fully
reported. Later evaluations and follow-up are conducted as
designed.Discontinuing evaluation
Psychiatric evaluation is discontinued if a participant
refuses to undergo evaluation. Investigators ask the par-
ticipants whether they can participate in later evalua-
tions and follow-up. The process for discontinuing
registration is initiated and reasons for the discontinu-
ation are fully reported. Later evaluations and follow-up
are conducted as designed.Discontinuing follow-up
Study participation is discontinued if a participant
refuses to be followed up. Investigators undertake the
process of discontinuing registration for follow-up and
record the relevant details. Later evaluations and follow-
up are not conducted.Retraction of consent
When a participant retracts his or her consent, all inter-
vention, evaluation, and follow-up is discontinued.
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When a participant deviates from the study protocol as
noted in the following, a follow-up session is conducted
as far as is possible: 1) capsules are not supplied or taken
as scheduled, 2) documents necessary for evaluation are
missing, and 3) continuing intervention is deemed diffi-
cult by the investigators for other reasons. Reasons for
the deviation are recorded.
Discontinuation of the study
The study is discontinued in the event of any of the
following.
1. The Data and Safety Monitoring Board recommends
discontinuation of the study.
2. Serious adverse events and side-effects occur that
make continuing the study difficult, and the Board
recommends discontinuation of the study.
3. The principal investigator decides to discontinue the
study.
Data and safety monitoring
The data manager provides a report using a pre-
determined template to the principal investigator and
the Data and Safety Monitoring Board on a regular basis
(once every 6 to 12 months). The Data and Safety Moni-
toring Board consists of the following three professionals
with experience in clinical trials, who are not involved in
this trial: Professor Yasuhiro Otomo (critical care medi-
cine), Dr. Tetsuo Nakabayashi (regulatory science), and
Professor Ataru Inagaki (psychopharmacology). The stat-
istical analysis manager reviews the reports filed by the
data manager in advance. Contents of the template in-
clude the following.
1. Study progress with case registration
2. Status of psychiatric evaluations and relevant issues
3. Occurrence of adverse events
4. Discussion of other relevant issues, problematic
cases, and events
Revision of the research plan and change of processes
The principal investigator will summon or e-mail inves-
tigators to discuss possible revisions to the research plan
when the regular monitoring report indicates the pres-
ence of serious adverse events or events that may affect
continuation of the study, thus suggesting safety pro-
blems in the study.
Data access and responsibility
Drs. Yutaka Matsuoka and Daisuke Nishi have full ac-
cess to all of the data in the study and take responsibility
for the integrity of the data and the accuracy of analysis.Presentation of the trial results
The findings will be presented in medical journals and at
academic conferences. The founding body will also be
notified of the results. An application for a press release
at the Press Club will be initiated if significant research
results are obtained and the study is accepted for publi-
cation by an influential academic journal. Mainly the
principal investigator is the corresponding author in all
presentations, and the first author and co-authors will
be determined according to their intellectual contribu-
tions. In addition, individuals who join the study after it
was approved and work fully toward the implementation
and progress of the study may obtain authorship with
the approval of the principal investigator.
Funding
This study was supported by CREST, the Japan Science
and Technology Agency (YM). The funding body peer
reviewed proposal documents which included digest ver-
sion of this study protocol as part of the selection
process. All of the supplements used in the study were
supplied by Kentech Co, Ltd., Toyama, Japan. They had
no role in the study design and conduct, in the collec-
tion, analysis and interpretation of the data, or in the
preparation, review, and approval of the manuscript.
Discussion
It is suggested that hippocampal neurogenesis may play
an important role in the periodic clearance of hippocam-
pal memory traces in contextual fear conditioning [36].
Thus, hippocampal neurogenesis is emerging as a pos-
sible mediator of the effect of omega-3 fatty acids on
fear memory. Modulating adult hippocampal neurogen-
esis by omega-3 fatty acid supplementation may well
then be a good target for the prevention of PTSD. Inter-
vention with omega-3 fatty acid appears acceptable in
broad clinical practice because of its convenience, em-
pirical results in animal studies, and much less serious
side effects than any psychotherapeutic drugs.
The TPOP study is designed to evaluate the efficacy of
omega-3 fatty acid supplementation for PTSD prevention
among injured patients. The open trial [38] provided prom-
ising support for our hypothesis: omega-3 fatty acid supple-
mentation significantly attenuated PTSD symptoms at 3
months as a primary outcome, as compared with the hypo-
thetical mean. We believe the results of the TPOP will be
of importance: accidental injury occurs across the globe
and omega-3 fatty acid supplementation, if found to be effi-
cacious for preventing PTSD, could maintain the mental
health of the injured.
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